id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S15758 R65134 |
Nehard, 2024 | Major congenital malformations (exclusion of chromosomal abnormalities or genetic defects) | 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Clomiphene exposure: Inadvertently during the first trimester of pregnancy (< 12 SA). Clomiphene indications: Inadvertently treated during pregnancy Matched | 0.79 [0.23;2.74] | 3/262 19/1,062 | 22 | 262 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15680 R64745 |
Weller, 2017 | All major malformations | preconceptional for kinetic reason | retrospective cohort | unexposed (general population or NOS) | Adjustment: Yes Clomiphene exposure: 2 months before conception through the first month of pregnancy Clomiphene indications: Not detailled but exclusion of in vitro fertilization (IVF) treatments | 1.12 [0.91;1.38] | 126/1,861 5,962/98,728 | 6,088 | 1,861 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S15714 R64913 |
Banhidy, 2008 | Congenital abnormality | early pregnancy | case control | unexposed (general population or NOS) | Adjustment: No Clomiphene exposure: Inadvertently during the first and second months of pregnancy. Clomiphene indications: Inadvertently treated during pregnancy Matched | 1.17 [0.85;1.59] C | 67/163 22,776/60,831 | 22,843 | 163 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 3 studies | 1.13 [0.95;1.34] | 28,953 | 2,286 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded